<DOC>
	<DOCNO>NCT00108875</DOCNO>
	<brief_summary>This study evaluate safety , immunological response clinical outcome vaccination survivin peptides patient advanced melanoma , pancreatic , colon cervical carcinoma .</brief_summary>
	<brief_title>Survivin Peptide Vaccination Patients With Advanced Melanoma , Pancreatic , Colon Cervical Cancer</brief_title>
	<detailed_description>As prognosis advance melanoma , pancreatic , colon cervical cancer remain gloomy , new therapeutic modality develop improve patientÂ´s clinical outcome . Immunotherapy , target tumor associate antigen tumor cell tumor stroma , currently intensively investigate , novel therapeutic option . As survivin express neoplastic cell well endothelial cell tumor vasculature , antigen intriguing target molecule . Spontaneous cytotoxic T-cell response different survivin epitope cancer patient underline relevance survivin-directed immunological trial . This study comprise peptide vaccine HLA-A1 , -A2 -B35 restrict survivin epitope Montanide ISA-51 patient stage IV melanoma , advance pancreatic , colon cervical carcinoma . The vaccine applicated deep subcutaneous injection . Vaccination administer first 2 month weekly , afterwards every 4 week . Standard stag examination perform every three month . Clinical , laboratory immunological monitoring do every month.Diagnostic leucapheresis perform first vaccination afterwards every 2 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Advanced melanoma , pancreatic , colon cervical cancer At least 1 prior postoperative conventional therapy ( chemotherapy , radiation , immunotherapy ) HLAA1 , A2 , B35 More 4 week since last chemo , immune radiotherapy ECOGPS ( Eastern Cooperative Oncology Group Performance Status ) 01 Sufficient renal , hepatic bone marrow function : thrombocyte &gt; 75.000/ul ; hb &gt; 9 g/dl ; leucocytes &gt; 2.500/ul ; creatinine &lt; 2 mg/dl ; GOT/GPT &lt; twice normal value negative HIV Hbs Older 18 year Informed consent Acute/chronic infection Positive HIV , Hbs Autoimmune disorder Pregnancy , breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>Peptide vaccine therapy</keyword>
	<keyword>Survivin</keyword>
</DOC>